In vitro comparison of two delivery devices for administering formoterol: Foradil® P and formoterol ratiopharm single-dose capsule inhaler

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 19, Issue 4, 2006, Pages 466-472

  Criée, Carl P ^a   Meyer, Thomas ^b,e   Petro, Wolfgang ^c   Sommerer, Knut ^b   Zeising, Peter ^d  

^a Sleep Laboratory   (Germany)

^b Inamed Research GmbH and Co KG   (Germany)

^c Klinik Bad Reichenhall   (Germany)

^d NOVARTIS PHARMA GMBH   (Germany)

^e Inamed GmbH   (Germany)

Author keywords

Aerolizer; Airflow resistance; Andersen Cascade Impactor; Formoterol; Lung deposition; Particle size; Ratiopharm single dose capsule inhaler

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; FORMOTEROL; FORMOTEROL FUMARATE;

AEROSOL; AIRFLOW; ARTICLE; BRONCHODILATATION; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; IN VITRO STUDY; INHALER; INSPIRATORY CAPACITY; MEASUREMENT; PARTICLE SIZE; SINGLE DRUG DOSE;

ADRENERGIC BETA-AGONISTS; ETHANOLAMINES; HUMANS; LUNG; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE;

EID: 33846052375     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.2006.19.466     Document Type: Article

References (32)

1. Ashurst, I., A. Malton, D. Prime, et al. 2000. Latest advances in the development of dry powder inhalers. Pharm. Sci. Technol. Today 3/7:246-256.
2. Newman, S.P., and W.W. Busse. 2002. Evolution of dry powder inhaler design, formulation, and performance. Respir. Med. 96:293-304.
3. Roche, N., and G.J. Huchon. 2000. Rationale for the choice of an aerosol delivery system. J. Aerosol Med. 13:393-404.
4. Labiris, N.R., and M.B. Dolovich. 2003. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 56:588-599.
5. Royal Society of Medicine. 2003. Effective Healthcare: Inhaler Devices for the Management of Asthma and COPD. Royal Society of Medicine Press Vol. 8, No. 1. London.
6. Dolovich, M. 1999. New propellant-free technologies under investigation. J. Aerosol Med. 12:S9-S17.
7. Labiris, N.R., and M.B. Dolovich. 2003. Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulation in the therapeutic effectiveness of aerolized medications. Br. J. Clin. Pharmacol. 56:600-612.
8. Wallin, A., T. Sandstrom, L. Rosenhall, et al. 1993. Time course and duration of action of bronchodilation with formoterol dry powder in patients with stable asthma. Thorax 48:611-614.
9. Bensch, G., R.J. Lapidus R.J., B.E. Levine, et al. 2001. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann. Allergy Asthma Immunol. 86:19-27.
10. Bensch, G., W.E. Berger, B.M. Blokhin, et al. 2002. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann. Allergy Asthma Immunol. 89:180-190.
11. Pleskow, W., C.F. LaForce, U. Yegen, et al. 2003. Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial. J. Asthma 40:505-514.
12. Dahl, R., L.A.P.M. Greefhorst, D. Nowak, et al. 5001. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 164:778-784.
13. Rossi, A., P. Kristofek, B. Levine, et al. 2002. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 121:1058-1069.
14. Gessner, C., S. Stenglein, M. Brautigam, et al. 2003. Miflonide/Foradil via Aerolizer compared with other anti-inflammatory and anti-obstructive therapeutic regimens. Pneumologie 57:137-143.
15. Clark, A.R., and A.M. Hollingworth. 1993. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-implications for in vitro testing. J. Aerosol Med. 6:99-110.
16. Barnes, P.J., C.B. Basbaum, J.A. Nadel, et al. 1982. Localization of beta-adrenoreceptors in mammalian lung by light microscopic autoradiography. Nature 299:444-447.
17. Ebina, M., H. Yaegashi, R. Chiba, et al. 1990. Hyperreactive site in the airway tree of asthmatic patients revealed by thickening of bronchial muscles. A morphometric study. Am. Rev. Respir. Dis. 141:1327-1332.
18. Zanen, P., L.T. Go, and J.-W.J. Lammers. 1994. The optimal particle size for β-adrenergic aerosols in mild asthmatics. Int. J. Pharm. 107:211-217.
19. Zanen, P., L.T. Go, and J.-W.J. Lammers. 1996. Optimal particle size for β2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax 51:977-980.
20. Usmani, O.S., M.F. Biddiscombe, J.A. Nightingale, et al. 2003. Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols. J. Appl. Physiol. 95:2106-2112.
21. 2- agonist particle size. Am. J. Respir. Crit. Care Med. 172:1497-1504.
22. Chege, J.K., and H. Chrystyn. 2000. The relative bioavailability of salbutamol to the lung using urinary excretion following inhalation from a novel dry powder inhaler: the effect of inhalation rate and formulation. Respir. Med. 94:51-56.
23. Clark, A.R. 1994. Effect of dry powder inhaler resistance upon inspiratory profiles in health and disease. Respir. Drug Deliv. 4:117-123.
24. Olsson, B., and L. Asking. 1994. Critical aspects of the function of inspiratory flow driven inhalers. J. Aerosol Med. 7:S43-S47.
25. Srichana, T., G.P. Martin, and C. Marriott. 1998. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur. J. Pharm. Sci. 7:73-80.
26. Bronsky, E.A., J. Grossman, M.M.J. Henis, et al. 2004. Inspiratory flow rates and volumes with the Aerolizer dry power inhaler in asthmatic children and adults. Curr. Med. Res. Opin. 20:131-137.
27. National Asthma Education and Prevention Program. 1998. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. U.S. Department of Health and Human Services, Public Health Service, Bethesda, MD. NIH Publication No. 98-4051.
28. de Koning, J.P., T.W. van der Mark, P.M.J. Coenegracht, et al. 2002. Effect of an external resistance to airflow on the inspiratory flow curve. Int. J. Pharm. 234:257-266.
29. Engel, T., J.H. Heinig, F. Madsen, et al. 1990. Peak inspiratory flow and inspiratory vital capacity of patients with asthma measured with and without a new dry-powder inhaler device (Turbuhaler). Eur. Respir. J. 3:1037-1041.
30. Pedersen, S., O.K. Hansen, and G. Fuglsang. 1990. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch. Dis. Child. 65:308-310.
31. Weuthen, T., S. Roeder, P. Brand, et al. 2002. In vitro testing of two formoterol dry powder inhalers at different flow rates. J. Aerosol Med. 15:297-303.
32. Chew, N.Y., and H.K. Chan. 2001. In vitro aerosol performance and dose uniformity between the Foradil Aerolizer and the Oxis Turbuhaler. J. Aerosol Med. 14:495-501.